NeuroFit, the first domestic company selected to participate in Roche Diagnostics Startup Innovation Program
Tuesday, September 05, 2023
Neurofit, a brain disease imaging artificial intelligence (AI) solution specialist, is the first Korean company to participate in the global startup innovation program 'Startup Cree' established by Roche, a leading global healthcare company, and Plug and Play, a global innovation platform. It was announced on the 5th that it was selected as a participating company in 'Startup Creasphere APAC 2023' (hereinafter referred to as Startup Creasphere).
As a company selected to participate in this program, Neurofit will jointly conduct research and development on brain image analysis technology with support from Roche Diagnostics' Asia Pacific regional headquarters. The technology being intensively researched and developed in this program is a technology that predicts the risk of amyloid beta protein, known as the causative agent of Alzheimer's disease, based on brain MRI (magnetic resonance imaging) analysis.
To determine whether Alzheimer's disease is confirmed, the degree of amyloid beta protein accumulated in the brain cortex is examined in amyloid-PET (positron emission tomography) images to determine whether the disease is positive or negative. However, amyloid-PET imaging is expensive, and in Korea, hospitals with PET imaging equipment are limited, so patients' access to medical care is significantly reduced. In addition, there are some patients who are reluctant to undergo PET imaging itself because radiation exposure to the patient is inevitable during PET imaging.
Neurofit plans to advance its brain image analysis AI technology and launch a product that can early predict amyloid beta protein positive risk groups through MRI analysis before amyloid-PET imaging. Since only about half of patients with mild cognitive impairment who are subject to amyloid-PET scans are positive for amyloid beta protein, the plan is to predict whether Alzheimer's disease is confirmed using MRI analysis alone, thereby reducing medical costs incurred from unnecessary amyloid-PET scans. Additionally, the strategy is to provide clinical support analysis services that can save clinical costs and time during clinical trials of anti-amyloid beta protein antibody treatments.
Crispher, a startup that NeuroFit is participating in this time, is one of the world's largest digital health solution innovation platforms established by Roche and Plug & Play. We operate a program to develop medical solutions and commercializable business models through joint research between competitive startups and global companies that develop innovative medical devices and digital healthcare technologies.
Approximately 107 startups have participated in the Startup Crispher Program, which started in 2018, and many startups have been matched with multinational healthcare companies such as Roche, Sanofi, and Novo Nordisk to conduct joint research and development and commercialization projects. there is.
Neurofit has been conducting research and development activities for about three months since the middle of last month with various support from Roche Diagnostics, including expert mentoring and global network exchange.
Neurofit CEO Bin Jun-gil said, “Neurofit’s outstanding brain image analysis technology was recognized by global pharmaceutical company Roche and we were selected for the Startup Innovation Program for the first time as a domestic company. Starting with selection for this program, we have opportunities for continued business cooperation with Roche in the future.” “We plan to create it,” he said.
He continued, “NeuroFit’s MRI and PET image analysis technology is expected to be used key in prescribing and observing prognosis for anti-amyloid beta protein antibody treatments such as lecanemab and donanemab, which have recently emerged as treatments for Alzheimer’s disease, and we are making every effort to advance the technology and commercialize the product. “It is a strategy to lean forward,” he emphasized.
Source: neurophet.com